Biotech Values

[mcbio]

Re: TLRs

• Jan 2007: Coley Pharmaceuticals drops Actilon, a TLR9 agonist that did not have much efficacy (#msg-16403804). Strike one.

• Jul 2007: ANDS discontinues ANA975, a TLR7 agonist that showed unacceptable liver toxicity (#msg-21600252). Strike two.

• Today: ANDS cans ANA773, a TLR7 agonist that’s the son of ANA975 (#msg-38418158). Strike three—you’re out!

Also, if the TLR7s are having issues with safety while the TLR9s are having efficacy issues, perhaps one can conclude that a TLR8 would strike the right balance?